Recruiting PHASE2 INTERVENTIONAL 3-arm
NCT06860529
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Sponsor: Henan Cancer Hospital
Conditions
HR+/HER2- Breast Cancer
Interventions
Albumin Paclitaxel Epirubicin Serplulimab
Updated 2 times since 2025 Last updated: Jun 20, 2025 Started: Apr 15, 2025 Primary completion: Mar 31, 2028 Completion: Mar 31, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates HR+/HER2- Breast Cancer and is currently actively recruiting participants. Henan Cancer Hospital leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
2 versions recorded-
Jul 2025 — Present [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2025 — Jul 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Henan Cancer Hospital
Data source: Henan Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .